title: Pharmacokinetics and body distribution of liposomal zinc phthalocyanine in tumor-bearing mice: influence of aggregation state, particle size, and composition.
abstract: The pharmacokinetics and body distribution of zinc phthalocyanine (ZnPc) intravenously administered in liposomes composed of ZnPc, 1-palmitoyl-2-oleoylphosphatidylcholine (POPC), and 1,2-dioleoylphosphatidylserine (OOPS) (1:90:10 or 1:70:30 w/w) to tumor (Meth A sarcoma) bearing mice were studied. It was found that aggregation of ZnPc in the liposomes (i) increases the clearance rate of the dye from plasma, (ii) lowers the maximal dye concentration in tumor tissue, and (iii) increases the maximal dye concentration in the liver. In addition, aggregated dye is hardly eliminated from the liver and monomeric dye is eventually completely eliminated from this organ. Liposomes in the size range of 48-123 nm, containing the dye with the same aggregation state, showed the same pharmacokinetics and body distribution of the dye. The PS-content of the ZnPc liposomes (POPC alone versus POPC/OOPS 7:3) did not influence tumor, liver, and plasma pharmacokinetics during the studied time intervals. Free flow electrophoretic analysis showed in lyophilisates of ZnPc liposomes containing aggregated ZnPc the presence of two distinct populations differing in size, aggregation state of the dye, and PC/PS and ZnPc/phospholipid ratio. The liposomal formulation with monomeric ZnPc has a compositional homogeneity and demonstrated selectivity and reached high uptake in tumors, 48 h after intravenous administration and appears promising for photodynamic therapy.
authors.affiliation: Research and Development Department, Ciba-Geigy Limited, Basle, Switzerland.
authors.forename: U
authors.initials: U
authors.lastname: Isele
authors.forename: K
authors.initials: K
authors.lastname: Schieweck
authors.forename: R
authors.initials: R
authors.lastname: Kessler
authors.forename: P
authors.initials: P
authors.lastname: van Hoogevest
authors.forename: H G
authors.initials: HG
authors.lastname: Capraro
mesh_terms: D000818:Animals; D004337:Drug Carriers; D004586:Electrophoresis; D005260:Female; D005612:Freeze Drying; D006207:Half-Life; D007211:Indoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D054833:Isoindoles; D007785:Lactose / Q000737:chemistry; D008081:Liposomes; D008099:Liver / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D010316:Particle Size; D010743:Phospholipids / Q000737:chemistry; D012513:Sarcoma, Experimental / Q000378:metabolism*; D013535:Suspensions; D014018:Tissue Distribution; D015032:Zinc / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D017967:Zinc Compounds
chemical_list: D004337:Drug Carriers; D007211:Indoles; D054833:Isoindoles; D008081:Liposomes; D009942:Organometallic Compounds; D010743:Phospholipids; D013535:Suspensions; D017967:Zinc Compounds; C052159:Zn(II)-phthalocyanine; D007785:Lactose; D015032:Zinc